Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264964 | 0.85 | USP7 (0.58) | LRRK2DHFRUSP7PIK3CD | |
| SCHEMBL17907568 | 0.84 | LMNA (0.54) | PIK3CADHFRACVR1 | |
| SCHEMBL2558872 | 0.81 | DHFR (0.60) | PIK3CADHFRPIK3CDMTOR | |
| SCHEMBL29557223 | 0.80 | ACHE (0.57) | ACVR1 | |
| SCHEMBL4473290 | 0.74 | POLB (0.53) | JAK2 | |
| SCHEMBL1612996 | 0.74 | PIK3CA (0.44) | PIK3CALRRK2DHFRMTOR | |
| SCHEMBL4472978 | 0.74 | HRH3 (0.56) | HRH3DHFR | |
| SCHEMBL13266893 | 0.74 | HRH3 (0.82) | HRH3JAK2 | |
| SCHEMBL2237239 | 0.74 | DHFR (0.54) | HRH3DHFR | |
| SCHEMBL15467001 | 0.72 | HRH3 (0.87) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | HRH3 1487/4885JAK2 1/4885PIK3CA 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.